Back to results
US 8,618,153 B2Granted
Hepatitis C virus inhibitors
AssigneeBristol-Myers Squibb Company
InventorsJohn A. Bender, Makonen Belema
Life of this patent
Estimating the term…
Abstract
This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Claims6
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- A-B is
- each R24 is independently selected from hydrogen and halo;
- wherein p is 0 or 1;
- R20 is selected from hydrogen and alkyl;
- R21 is selected from hydrogen and alkyl;
- R22 is hydrogen or —C(O)Rx;
- and
- R23 is selected from hydrogen and alkyl, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups;
- R2 is hydrogen or —C(O)Ry;
- Rx and Ry are each independently selected from cycloalkyl, heteroaryl, heterocyclyl, alkoxy, and alkyl, said alkyl being substituted by one or more substituents independently selected from aryl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl, —OR3, —NRaRb, and —C(O)NRcRd,
- wherein any said aryl and heteroaryl may optionally be substituted with one or more substituents independently selected from alkenyl, alkyl, haloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, —C(O)OR4, OR5, —NRaRb, (NRaRb)alkyl, and (MeO)(HO)P(O)O—, and
- wherein any said cycloalkyl and heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one or more substituents independently selected from alkoxy, alkyl, hydroxyl, halogen, aryl, —NRaRb, oxo, and —C(O)OR4;
- R3 is hydrogen, alkyl, or arylalkyl;
- R4 is selected from alkyl and arylalkyl;
- R5 is hydrogen, alkyl, or arylalkyl;
- Ra and Rb are independently selected from hydrogen, alkyl, cycloalkyl, arylalkyl, heteroaryl, —C(O)R6, —C(O)OR7, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, aryl, hydroxyl, C1 to C6 alkoxy, C1 to C4 haloalkoxy, and halogen;
- R6 is alkyl;
- R7 is alkyl, cycloalkyl, arylalkyl, or haloalkyl;
- and
- Rc and Rd are independently selected from hydrogen, alkyl, arylalkyl, and cycloalkyl.
18 more elements
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
- Methyl ((1S)-1-(((2S)-2-(4-(4′-((2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)ethynyl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate;
- and corresponding stereoisomers and tautomers thereof.
Dependencies are inferred from the claim text.